Page 15 - Pharma Services News Today

Yarbrough Capital LLC bought a new stake in NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,572 shares of the medical research company’s stock, valued at approximately $376,000. Other large investors have also recently bought […]

/PRNewswire/ -- The "Clinical Trial Packaging and Labelling Market Report 2023-2033" report has been added to ResearchAndMarkets.coms offering. Overall world...

Toronto, ON (PRWEB) June 15, 2023 -- How does a CDMO ensure the successful development and manufacture of breakthrough discoveries? Could drug development

First Light Asset Management LLC cut its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,682,171 shares of the medical research company’s stock after selling 37,928 shares during […]

A PHARMA services company based in Hartley Wintney has strengthened its team with a raft of senior hires as it continues to grow internationally.

/PRNewswire/ -- The cold chain logistics market for pharmaceuticals industry is estimated to grow by USD 11.6 billion during 2022-2027. The growth momentum...

NeoGenomics (NASDAQ:NEO – Get Rating) updated its FY 2023 earnings guidance on Wednesday. The company provided EPS guidance of -$0.36–$0.30 for the period, compared to the consensus EPS estimate of -$0.42. The company issued revenue guidance of $555.00 million-$565.00 million, compared to the consensus revenue estimate of $549.82 million. Analyst Upgrades and Downgrades A number […]

NeoGenomics (NASDAQ:NEO – Get Rating) issued an update on its FY 2023 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -$0.36–$0.30 for the period, compared to the consensus estimate of -$0.42. The company issued revenue guidance of $555.00 million-$565.00 million, compared to the consensus revenue estimate of $549.82 million. […]

/PRNewswire/ -- What is the Overview of Cell and Gene Therapy CDMO Market? Cell and gene therapies (CAGT) are used in treating various diseases like heart...

NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that […]